This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute, Naples Identifier:
First received: November 17, 2006
Last updated: July 12, 2012
Last verified: July 2012
The combination of vinorelbine with weekly trastuzumab has produced high response rate in HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to test activity of the same combination, with trastuzumab given every 3 weeks, rather than weekly.

Condition Intervention Phase
Metastatic Breast Cancer Drug: trastuzumab Drug: vinorelbine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2

Resource links provided by NLM:

Further study details as provided by National Cancer Institute, Naples:

Primary Outcome Measures:
  • response rate
  • toxicity

Secondary Outcome Measures:
  • time to progression
  • overall survival

Estimated Enrollment: 50
Study Start Date: November 2002
Study Completion Date: December 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Detailed Description:
The schedule of treatment includes vinorelbine (30 mg/m2 on days 1 & 8 every 21 days) and trastuzumab (8 mg/kg on day 1 and then 6 mg/kg every 21 days). Vinorelbine is planned for maximum 9 cycles, while trastuzumab can be continued until progression. This study is a single-stage phase 2 design, and patients eligible for response evaluation are required.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed breast cancer
  • Stage IV
  • No prior or not more than one prior chemotherapy for metastatic disease
  • Overexpression of HER-2 (3+ on immunohistochemical exam) or amplified genetic expression of c-erbB2/neu (positive by Fish method)
  • Performance status 0-2 (ECOG)

Exclusion Criteria:

  • Absence of measurable disease
  • Life expectancy < 3 months
  • Concomitant malignancy or malignancy within previous 5 years (except basal cell or spinocellular skin cancer and in situ cervical cancer if they have been adequately treated
  • Previous treatment with trastuzumab or vinorelbine
  • Neutrophils < 1500/mm3 or platelets < 100000/mm3 or haemoglobin < 8 g/dl
  • Creatinine > 1.5 x the value of the upper normal limit
  • GOT and/or GPT > 2.5 x the value of the upper normal limit and/or bilirubin > 1.5 x the value of the upper normal limit in the absence of liver metastases
  • GOT and/or GPT > 5 x the value of the upper normal limit and/or bilirubin > 3 x the value of the upper normal limit in the presence of liver metastases
  • Left ventricular ejection fraction < 50% (measured by ultrasound or MUGA angiography)
  • Concomitant conditions that contraindicate the use of the drugs in the protocol
  • Male gender
  • Pregnancy or lactation·
  • Incapacity or refusal to provide informed consent
  • Inability to comply with followup
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00401427

Sponsors and Collaborators
National Cancer Institute, Naples
Principal Investigator: Andrea De Matteis, M.D. NCI Naples, Division of Medical Oncology C
Principal Investigator: Francesco Perrone, M.D., Ph.D. NCI Naples, Clinical Trials Unit
  More Information

Responsible Party: National Cancer Institute, Naples Identifier: NCT00401427     History of Changes
Other Study ID Numbers: HERVIN
Study First Received: November 17, 2006
Last Updated: July 12, 2012

Keywords provided by National Cancer Institute, Naples:
HER2 overexpression
combination therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017